Chugai Pharmaceutical and Biomy Partner to Develop AI-Powered Cancer Pathology Diagnostic Support Programs
核心洞察
Chugai Pharmaceutical and Biomy (搜索) have signed a memorandum of understanding to jointly develop AI-based cancer pathology diagnostic support programs addressing the growing shortage of pathologists and increasing diagnostic workload.
The partnership will create two innovative AI programs: one for neoadjuvant therapy efficacy assessment and another for tumor microenvironment analysis to predict prognosis and drug efficacy.
The collaboration combines Chugai's oncology expertise with Biomy (搜索)'s cutting-edge AI technology platform to standardize pathological diagnosis and improve treatment decision-making for cancer patients.
Chugai Pharmaceutical Co., Ltd. and Biomy (搜索), Inc. announced they have entered into a Memorandum of Understanding for the joint development of AI-based cancer pathology diagnostic support programs. The partnership addresses critical healthcare challenges including the heavy burden of pathological diagnosis due to increasing cancer cases and the growing shortage of pathologists who play crucial roles in cancer diagnosis and treatment decisions.
Addressing Critical Healthcare Challenges
The collaboration comes at a time when pathological diagnosis workload has increased significantly due to rising cancer cases, while there is a growing shortage of pathologists. As personalized healthcare and digital technology advance, diagnostic and treatment needs are diversifying, with rising expectations for rapid and accurate diagnosis amid the advancement of pathological diagnostics. The development of AI-based pathological diagnostic support solutions is expected to significantly contribute to the standardization and increased efficiency of diagnosis while improving the quality of treatment decisions.
Two Innovative AI Programs in Development
The partnership will develop two AI-based pathology programs by integrating Chugai's scientific knowledge cultivated through years of business activities in the oncology field with Biomy (搜索)'s platform for tumor microenvironment analysis powered by cutting-edge AI technology.
Neoadjuvant Therapy Efficacy Assessment Support Program
The first program focuses on pathologic response assessment to evaluate the therapeutic effect of pharmacotherapy administered before cancer surgery (neoadjuvant therapy). This assessment provides important information related to the patient's post-operative treatment plan and prognosis. However, current challenges include variability among evaluators as well as heavy burden, such as time and effort, on pathologists. This program intends to reduce the burden on pathologists while enabling resource concentration on difficult-to-differentiate cases and genomic diagnoses, thereby improving pathological diagnosis throughput and standardizing pathologic response assessment.
Tumor Microenvironment Analysis Program
The second program addresses the tumor microenvironment—composed of tumor tissue or cancer cells along with surrounding immune cells and normal cells—which has gained attention for its association with patient prognosis and the efficacy of drugs such as immune checkpoint inhibitors. This program aims to contribute to patient care by using AI to analyze the tumor microenvironment from pathological images, supporting the detection of important features related to patient prognosis and drug efficacy, while maximizing the value of personalized healthcare and pharmaceuticals.
Leadership Perspectives
Dr. Osamu Okuda, Chugai's President and CEO, emphasized the importance of pathological diagnosis in advancing personalized healthcare: "Chugai aims to advance personalized healthcare, and for this purpose, pathological diagnosis that supports treatment decision-making and evaluation of therapeutic effects is extremely important. In the oncology field, our company has cultivated scientific knowledge through experiences in drug development and clinical applications, evaluation of treatment effectiveness in clinical practice, and recognition of challenges in pathological diagnosis. In this joint development, we will utilize this knowledge through cross-industry collaboration and strive to enhance pathological diagnosis and maximize value for patients."
Teppei Konishi, President and CEO of Biomy (搜索), highlighted the significance of the partnership: "We are deeply honored to have entered into this Memorandum of Understanding with Chugai Pharmaceutical. Biomy was founded with the mission of pioneering the future of precision medicine through pathology AI. This project represents a groundbreaking step in realizing that vision, and we are confident that it will demonstrate to the world the new possibilities of medicine. By combining the respective strengths of a pharmaceutical company and an AI company, we aim to accelerate medical innovation and deliver truly optimal treatment to each individual patient around the world."
Strategic Impact
Through this initiative, both companies aim to reduce the workload of pathologists and provide optimal treatment and diagnosis for individual patients. The collaboration represents a cross-industry approach to implementing personalized healthcare solutions that will contribute to providing optimal treatment for patients with cancer. Chugai will continue to deepen cross-industry partnerships and strive to make contributions to patients and healthcare systems through this and similar initiatives.